Evaluation of niraparib 200 mg/d as maintenance therapy in recurrent ovarian cancer and associated thrombocytopenia in a real-world US setting
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz250.013
Abstract: Abstract Background Niraparib, a poly(ADP-ribose) polymerase inhibitor approved in 2017 by the US FDA (300 mg/d), has proven to be efficacious as maintenance therapy in patients (pts) with recurrent epithelial ovarian, fallopian tube, or primary peritoneal… read more here.
Keywords: full part; time; part time; oncology ... See more keywords
Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.25
Abstract: Introduction/Background In the phase III GOG240 trial, combining bevacizumab with paclitaxel and cisplatin/topotecan for advanced cervical cancer significantly improved overall and progression-free survival. The single-arm phase II CECILIA study (NCT02467907) evaluated bevacizumab with a more… read more here.
Keywords: bevacizumab; cervical cancer; roche; tesaro ... See more keywords
Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.28
Abstract: Introduction/Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo in all patient populations, regardless of biomarker status (Coleman et al. Lancet. 2017;390:1949–61). This subgroup analysis examined the effect of the stratification… read more here.
Keywords: pfi; astrazeneca; clovis; clovis astrazeneca ... See more keywords